Early, Sustained, and Comprehensive Control of Lipids and Health: From Therapies to Models of Care

Program Overview

The National Lipid Association and European Atherosclerosis Society partnered to offer a two-part symposium series to provide an in-depth exploration of lipid-modifying therapies, targeting various lipid components and considering holistic models of care for effective lipid management. Attendees will gain insights from leading experts on LDL-C reduction, the role of remnant cholesterol and triglyceride-rich lipoproteins, the latest advances in the role of Lp(a) in both risk assessment and treatment, and systems approaches to improving lipid management.

View Recording

Target Audience

This initiative has been designed to address the educational needs of cardiology clinicians, including physicians, nurse practitioners (NPs), PAs, and clinical pharmacists. It may also benefit primary care practitioners (PCPs) and other clinicians who are interested or involved in the care of patients with risk factors for cardiovascular disease.

 

Faculty:

Borge G. Nordestgaard, MD, DMSc
President, European Atherosclerosis Society
Professor and Chief Physician
Copenhagen University Hospital
University of Copenhagen 

Professor Kausik Ray MD FMedSci
Immediate Past President EAS
Professor of Public Health
Imperial College London
London, UK

Christie M. Ballantyne, MD, FNLA
Past President, National Lipid Association
Chief, Section of Cardiovascular Research
Director, Center for Cardiometabolic Disease Prevention
Professor of Medicine, Molecular and Human Genetics, and Integrative Physiology
Baylor College of Medicine
Houston, TX

Kaye Eileen Willard, MD, FNLA
President, National Lipid Association
Medical Director Lipid Clinic
Physician Advisor, Ascension SE Wisconsin
Chief of Staff Ascension All Saints
Chair Joint Chiefs of Staff Ascension SE Wisconsin
Racine, WI

 

Agenda:

5 minutes	Welcome and Session Introduction>
15 minutes	LDL-C Reduction	Prof. Kausik Ray
15 minutes	Remnant Cholesterol and Triglyceride-Rich Lipoproteins	Dr. Borge Nordestgaard
15 minutes	Lp(a) Management	Dr. Christie Ballantyne
15 minutes	Systems Approaches to Improving Lipid Management	Dr. Kaye Eileen Willard
10 minutes	Audience Q+A	All Speakers

 

Learning Objectives

1. Identify LDL-C as a primary target in lipid management and evaluate strategies for early intervention and sustained control to mitigate cardiovascular risk.
2. Examine the implications of remnant cholesterol and triglyceride-rich lipoproteins on cardiovascular health and explore current therapeutic strategies targeting these lipid components
3. Analyze the role of lipoprotein(a) in cardiovascular risk assessment and review current and emerging therapies tailored to Lp(a) management.
4. Assess integrated care models and population health strategies, including the use of health data for identifying and managing high-risk patients, to enhance lipid management outcomes on a systemwide scale.
5. Discuss strategies to improve the knowledge, skills or performance of the healthcare team.